Manoussos Perros
Chief Executive Officer chez ENTASIS THERAPEUTICS HOLDINGS INC.
Profil
Manoussos Perros is the founder of Entasis Therapeutics, Inc. which was founded in 2015.
He is currently the President, Chief Executive Officer & Director at Entasis Therapeutics Holdings, Inc. and a Director at Entasis Therapeutics Ltd.
He previously worked as a Director at Novartis Institute for Tropical Diseases Pte Ltd.
and as the Chief Scientific Officer & Vice President at Pfizer Inc. He was also the Vice President & Head-Infection Research at AstraZeneca AB from 2010 to 2015 and an Associate at Yale University from 1993 to 1995.
Postes actifs de Manoussos Perros
| Sociétés | Poste | Début |
|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Chief Executive Officer | 01/05/2015 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Founder | 01/05/2015 |
Entasis Therapeutics Ltd.
 Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., Entasis Therapeutics Ltd. is a British pharmaceutical company founded in 2015. The private company is based in Altrincham, UK and manufactures and distributes pharmaceutical products. | Director/Board Member | 11/05/2015 |
Anciens postes connus de Manoussos Perros
| Sociétés | Poste | Fin |
|---|---|---|
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | 01/01/2015 |
| Yale University | Corporate Officer/Principal | 01/01/1995 |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | - |
Novartis Institute for Tropical Diseases Pte Ltd.
 Novartis Institute for Tropical Diseases Pte Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Institute for Tropical Diseases Pte Ltd. is a Singaporean company that develops novel small molecule therapies for tropical infectious diseases. The private company is based in Singapore, Singapore. | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Novartis Institute for Tropical Diseases Pte Ltd.
Novartis Institute for Tropical Diseases Pte Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Institute for Tropical Diseases Pte Ltd. is a Singaporean company that develops novel small molecule therapies for tropical infectious diseases. The private company is based in Singapore, Singapore. | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Ltd.
Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., Entasis Therapeutics Ltd. is a British pharmaceutical company founded in 2015. The private company is based in Altrincham, UK and manufactures and distributes pharmaceutical products. | Health Technology |
